U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C20H20N2O2
Molecular Weight 320.385
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FEPRAZONE

SMILES

CC(C)=CCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3

InChI

InChIKey=RBBWCVQDXDFISW-UHFFFAOYSA-N
InChI=1S/C20H20N2O2/c1-15(2)13-14-18-19(23)21(16-9-5-3-6-10-16)22(20(18)24)17-11-7-4-8-12-17/h3-13,18H,14H2,1-2H3

HIDE SMILES / InChI
Molecular Formula C20H20N2O2
Molecular Weight 320.385
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Feprazone is an anti-inflammatory compound developed for the treatment of such conditions as osteoarthritis, rheumatoid arthritis, rheumatic fever and gouty arthritis. The drug was tested in phase III of clinical trials, however its further faith is unknown.

Originator

Casadio, S. et al.
1

Approval Year

Unknown
139,594

Conditions

ConditionModalityTargetsHighest PhaseProduct
Rheumatoid arthritis
316
 Palliative
Phase III
656
Unknown
Osteoarthritis
157
 Palliative
Phase III
656
Unknown
Rheumatic fever
6
 Palliative
Phase III
656
Unknown
Gouty arthritis
4
 Palliative
Phase III
656
Unknown

PubMed

Patents

JPS61130221A
1

Sample Use Guides

In Vivo Use Guide
150 mg four times daily.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Record UNII
7BVX6J0CGR
Record Status Validated (UNII)
Record Version
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966